Friday, February 19, 2016

$22.7 billion ...


... are the estimated savings that biosimilar versions of Neupogen ($5.7 billion) and Remicade ($17 billion) will yield during the first decade they are on the market, according to an analysis by Express Scripts Holding Co.

No comments:

Post a Comment